O

ORIC

ORIC

UnknownUnknown

Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.

Insider Sentiment
Based on recent trading activity
5%Bearish
Buy/Sell Ratio4% buys
BearishBullish
ORIC Live QuoteReal-time
$7.70
$6.15(-44.40%)1M
Day Range$7.53 – $7.98
Open$7.86
Previous Close$7.65
Volume1.07M
Key Financials & Valuation
Fundamental balance sheet & market metrics
HEALTHCARE
Market Cap$795.08M
P/E Ratio (TTM)24.5
Forward P/ENaN
EPS (TTM)$-1.44
Price to Book2.4
Dividend Yield0.65%
Beta (Volatility)1.21
IndustryBIOTECHNOLOGY
52-Week RangeCurrent: $7.70 (6%)
Low: $7.23High: $14.68
Wall Street Consensus
Sell
Analyst Rating
2.2/ 5.0
Target Price
$21.79-85.5% upside

Insider Buys

1

$263K

Insider Sales

24

$6.95M

Total Volume

$7.22M

25 transactions

Net Activity

$6.69M

Net selling

Proprietary Ratings
Calculated from Form 4 transactions
25CONFIDENCE

Sentiment Rating

Moderate Distribution

CEO Conviction Index

Liquidating / Profit Taking

Key Drivers

  • •Heavy distribution: sales represent 96% of total transaction value.
  • •CEO selling activity detected. Often driven by option expiration or diversification plans.
Score Methodology

The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:

  • +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
  • +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
  • +15CEO Buying: CEO committing own capital shows high conviction.
  • +10CFO Buying: CFO purchasing shares shows financial alignment.
Top Insiders
Most active traders
C
1

Chacko Jacob

Pres, CEO

0 buys5 sells

$3.37M total

P
2

Piscitelli Dominic

CFO

0 buys13 sells

$3.08M total

H
3

Heyman Richard A.

Dir

0 buys4 sells

$328K total

Y
4

You Angie

Dir

1 buys0 sells

$263K total

M
5

Multani Pratik S

Chief Medical Officer

0 buys2 sells

$170K total

Trading History
ORIC insider transactions from SEC Form 4 filings
DateInsiderTypeSharesPriceValueFiling

Oct 20, 2026

1 months ago

Piscitelli Dominic

CFO

CFO
Sell14.0K$13.53$189K

Oct 1, 2026

1 months ago

Heyman Richard A.

Dir

Director
Sell6.7K$12.91$87K

Sep 28, 2026

1 months ago

Piscitelli Dominic

CFO

CFO
Sell13.4K$13.53$181K

Sep 24, 2026

1 months ago

Piscitelli Dominic

CFO

CFO
Sell600$13.50$8K

Aug 26, 2026

2 months ago

Piscitelli Dominic

CFO

CFO
Sell77.0K$13.69$1.05M

Jul 24, 2026

3 months ago

Heyman Richard A.

Dir

Director
Sell13.1K$12.02$157K

Jul 6, 2026

4 months ago

Heyman Richard A.

Dir

Director
Sell300$12.00$4K

Feb 24, 2026

8 months ago

Piscitelli Dominic

CFO

CFO
Sell52.0K$13.51$703K

Jan 16, 2026

10 months ago

Heyman Richard A.

Dir

Director
Sell6.7K$12.00$80K

Dec 16, 2025

11 months ago

Multani Pratik S

Chief Medical Officer

C-Level
Sell10.7K$9.06$97K

Dec 16, 2025

11 months ago

Piscitelli Dominic

CFO

CFO
Sell10.7K$9.06$97K

Dec 16, 2025

11 months ago

Chacko Jacob

Pres, CEO

CEO
Sell33.4K$9.06$302K

Oct 6, 2025

13 months ago

Piscitelli Dominic

CFO

CFO
Sell11.0K$14.52$160K

Oct 6, 2025

13 months ago

Chacko Jacob

Pres, CEO

CEO
Sell37.5K$12.32$462K

Sep 30, 2025

13 months ago

Chacko Jacob

Pres, CEO

CEO
Sell87.5K$12.04$1.05M

Sep 22, 2025

14 months ago

Chacko Jacob

Pres, CEO

CEO
Sell125.0K$10.80$1.35M

Jul 1, 2025

16 months ago

Piscitelli Dominic

CFO

CFO
Sell20.0K$10.05$201K

Jun 23, 2025

17 months ago

Piscitelli Dominic

CFO

CFO
Sell33.5K$10.49$351K

Jun 20, 2025

17 months ago

You Angie

Dir

Director
Buy28.0K$9.39$263K

Jun 12, 2025

17 months ago

Piscitelli Dominic

CFO

CFO
Sell300$10.00$3K

Jun 10, 2025

17 months ago

Piscitelli Dominic

CFO

CFO
Sell3.3K$10.01$33K

Jun 6, 2025

17 months ago

Piscitelli Dominic

CFO

CFO
Sell2.9K$10.01$29K

Dec 16, 2024

23 months ago

Piscitelli Dominic

CFO

CFO
Sell8.9K$8.28$73K

Dec 16, 2024

23 months ago

Multani Pratik S

Chief Medical Officer

C-Level
Sell8.8K$8.28$73K

Dec 16, 2024

23 months ago

Chacko Jacob

Pres, CEO

CEO
Sell24.7K$8.28$204K
Sector & Industry Benchmarks
Unknown Comparison Overview
Industry Buy Conviction6%
ORIC Buy Conviction4%
Industry Rank#0 of 570
Volume Contribution0.0%
Total Industry Activity$16.44B

ORIC has an insider buy conviction of 4%, compared to the Unknown sector buy average of 6%.

Insider Trading Summary & Commentary
Automated executive transaction analysis for ORIC

Over the last 90 days, corporate insiders at ORIC (ORIC) engaged in a total of 25 transactions reported via SEC Form 4 filings. Among these, 1 were open-market purchases and 24 were sales. The total volume of insider trading reached $7.22M.

The net insider activity for ORIC shows a net selling bias of $6.69M. This activity represents a 4% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.

The most notable individual transaction was a Sale by Chacko Jacob (Pres, CEO), who traded 125.0K shares valued at $1.35M on Sep 22, 2025.

Live Market News & Developments
Aggregated real-time headlines for ORIC (ORIC)
6 updates

symbol__ Stock Quote Price and Forecast

CNNYesterday

ORIC Pharmaceuticals, Inc. (ORIC) Stock Price, News, Quote & History

Yahoo! Finance Canada2d ago

ORIC Pharmaceuticals, Inc. (ORIC) stock price, news, quote and history

Yahoo Finance UK2d ago

Oric Pharmaceuticals stock maintained at Buy by BTIG, $26 target

Investing.com2d ago

Oric Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $21.79, Implies 190% Upside

TradingView2d ago

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Price Target Lowered at HC Wainwright

MarketBeat11h ago

Related News & Analyst Reports

Read original insights and educational research covering ORIC and the Unknown sector.

March 20, 2026

Sequoia Capital and the Mechanics of Venture Lock-Up Extensions

Sequoia Capital pioneered the use of voluntary lock-up extensions to signal portfolio company confidence. This report analyzes the market-price impact of Sequoia extension announcements and whether they have historically justified the delay.

Read Analysis
March 12, 2026

Unusual Insider Buying Patterns: Spotting the Anomalies

Beyond simple purchase screens, unusual insider buying patterns, accelerating purchase velocity, off-hours filings, purchases during active 10b5-1 plans, can reveal extraordinary conviction. This guide documents nine pattern types and their historical signal accuracy.

Read Analysis
August 30, 2024

Why Biotech Insiders Purchase Prior to Phase 3 Results

Buying stock before Phase 3 results is the highest-risk insider trade in biotech. This report examines the legal boundaries, the statistical frequency of such purchases, and whether insiders who buy pre-Phase-3 have historically outperformed those who buy after.

Read Analysis
April 7, 2024

How to Use Insider Buying Data to Minimize Portfolio Downside

Insider buying clusters have historically preceded significant price recoveries after drawdowns. This risk-management guide shows how to overlay Form 4 data with portfolio holdings to reduce downside exposure at sector and position level.

Read Analysis
May 23, 2023

Why C-Suite Buying During Market Corrections is a Strong Buy Signal

C-suite executives buying their own stock during broad market corrections have historically generated some of the strongest insider-signal returns. This report analyzes the 2020 COVID crash, the 2022 rate-shock selloff, and three prior corrections using Form 4 data.

Read Analysis
January 16, 2023

Tracking Insiders in the Energy Sector: Key Indicators to Watch

Energy insiders, especially at exploration and production companies, show highly seasonal and commodity-correlated trading patterns. This report identifies the Form 4 signals in energy stocks that have historically preceded oil-price-driven rallies and sector-specific recoveries.

Read Analysis

FAQs About ORIC Insider Trading

Answers to common questions regarding corporate filings and executive sentiment for ORIC.

Based on SEC Form 4 disclosures, the Insider Confidence Score for ORIC is currently 25/100, which reflects a moderate distribution bias. This calculation accounts for a total of 1 purchases and 24 sales by company executives over the last 90 days.

The CEO Conviction Index for ORIC is rated as "Liquidating / Profit Taking". Executive buying is typically a strong vote of confidence as C-level leaders have the most intimate knowledge of their firm's prospects. Officer selling, on the other hand, is often routine and does not automatically signal operational weakness.

No. Insider tracking is a highly informative technical signal that indicates executive sentiment, but it should not be the sole basis for a transaction. Investors should combine this filing analysis with company financials, sector trends, and risk management criteria.